Brevan Howard Capital Management LP lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 38.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,707 shares of the medical research company's stock after selling 2,300 shares during the period. Brevan Howard Capital Management LP's holdings in Thermo Fisher Scientific were worth $1,928,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of TMO. Cantor Fitzgerald L. P. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $520,000. Cary Street Partners Financial LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $16,658,000. Chapman Financial Group LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $2,631,000. Baldwin Investment Management LLC grew its holdings in Thermo Fisher Scientific by 14.4% during the 4th quarter. Baldwin Investment Management LLC now owns 8,879 shares of the medical research company's stock valued at $4,619,000 after buying an additional 1,119 shares during the last quarter. Finally, Banque Transatlantique SA acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $79,041,000. 89.23% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, SVP Michael A. Boxer sold 3,775 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares of the company's stock, valued at $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,075 shares of company stock worth $7,305,942 in the last three months. 0.33% of the stock is owned by insiders.
Wall Street Analyst Weigh In
A number of analysts recently commented on TMO shares. Raymond James reiterated an "outperform" rating and set a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Royal Bank of Canada cut their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Scotiabank lowered their target price on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research note on Friday, April 25th. Argus reduced their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Finally, Morgan Stanley increased their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average price target of $607.43.
Get Our Latest Stock Report on TMO
Thermo Fisher Scientific Stock Down 1.9 %
TMO traded down $7.85 on Friday, reaching $402.93. The company's stock had a trading volume of 2,318,607 shares, compared to its average volume of 1,797,672. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 1 year low of $401.75 and a 1 year high of $627.88. The business's 50 day moving average is $464.67 and its 200 day moving average is $515.28. The stock has a market cap of $152.10 billion, a price-to-earnings ratio of 24.38, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. During the same quarter last year, the company posted $5.11 earnings per share. The company's quarterly revenue was up .2% compared to the same quarter last year. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.
Thermo Fisher Scientific Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were paid a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.43%. Thermo Fisher Scientific's dividend payout ratio is 10.09%.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
